Viking Therapeutics Yönetim
Yönetim kriter kontrolleri 2/4
Viking Therapeutics' CEO is Brian Lian, appointed in Sep 2012, has a tenure of 12.17 years. total yearly compensation is $12.63M, comprised of 4.9% salary and 95.1% bonuses, including company stock and options. directly owns 1.71% of the company’s shares, worth $139.16M. The average tenure of the management team and the board of directors is 5.3 years and 10.5 years respectively.
Anahtar bilgiler
Brian Lian
İcra Kurulu Başkanı
US$12.6m
Toplam tazminat
| CEO maaş yüzdesi | 4.9% |
| CEO görev süresi | 12.2yrs |
| CEO sahipliği | 1.7% |
| Yönetim ortalama görev süresi | 5.3yrs |
| Yönetim Kurulu ortalama görev süresi | 10.5yrs |
Son yönetim güncellemeleri
Recent updates
Viking Therapeutics: Too Much Excitement Around Oral VK2735, Even If It Met High Expectations
Nov 04Viking Therapeutics: Lots Of Positives
Oct 28Viking Therapeutics: Market Rightly Excited By GLP-1 Promise -- A Buy Ahead Of Data
Sep 25Companies Like Viking Therapeutics (NASDAQ:VKTX) Can Afford To Invest In Growth
Sep 07
Viking Therapeutics: GLP-1/GIP Receptor Agonist And Its Competitive Landscape
Aug 30Viking Therapeutics: Better-Than-Expected Trial Timelines While Pipeline Expands
Jul 25We Think Viking Therapeutics (NASDAQ:VKTX) Can Easily Afford To Drive Business Growth
Apr 26Viking Therapeutics: Future Weight Loss Heavyweight?
Apr 02We're Hopeful That Viking Therapeutics (NASDAQ:VKTX) Will Use Its Cash Wisely
Jan 09We're Not Very Worried About Viking Therapeutics' (NASDAQ:VKTX) Cash Burn Rate
Sep 21Viking Therapeutics (NASDAQ:VKTX) Is In A Good Position To Deliver On Growth Plans
Jun 07We're Not Very Worried About Viking Therapeutics' (NASDAQ:VKTX) Cash Burn Rate
Mar 05Viking Therapeutics: Playing Second Fiddle To Madrigal
Aug 30We Think Viking Therapeutics (NASDAQ:VKTX) Can Afford To Drive Business Growth
Jul 13Revisiting Viking Therapeutics
Apr 20We Think Viking Therapeutics (NASDAQ:VKTX) Can Afford To Drive Business Growth
Apr 12We Think Viking Therapeutics (NASDAQ:VKTX) Can Afford To Drive Business Growth
Dec 17Viking Therapeutics: Remaining Bullish And Sticking To My Plan
Aug 27Viking Therapeutics soars 11% on encouraging VK0214 data in rare metabolic disorder
Jun 17Have Insiders Been Selling Viking Therapeutics, Inc. (NASDAQ:VKTX) Shares This Year?
Jan 13Viking Therapeutics announces senior management appointments
Jan 06Do Institutions Own Viking Therapeutics, Inc. (NASDAQ:VKTX) Shares?
Dec 09
Viking Therapeutics: Progressing Steadily, But Concerns Remain
Nov 29CEO Tazminat Analizi
| Tarih | Toplam Tazminat | Maaş | Şirket Kazançları |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$99m |
| Jun 30 2024 | n/a | n/a | -US$97m |
| Mar 31 2024 | n/a | n/a | -US$94m |
| Dec 31 2023 | US$13m | US$615k | -US$86m |
| Sep 30 2023 | n/a | n/a | -US$81m |
| Jun 30 2023 | n/a | n/a | -US$74m |
| Mar 31 2023 | n/a | n/a | -US$72m |
| Dec 31 2022 | US$5m | US$612k | -US$69m |
| Sep 30 2022 | n/a | n/a | -US$62m |
| Jun 30 2022 | n/a | n/a | -US$59m |
| Mar 31 2022 | n/a | n/a | -US$57m |
| Dec 31 2021 | US$4m | US$594k | -US$55m |
| Sep 30 2021 | n/a | n/a | -US$54m |
| Jun 30 2021 | n/a | n/a | -US$50m |
| Mar 31 2021 | n/a | n/a | -US$44m |
| Dec 31 2020 | US$5m | US$577k | -US$39m |
| Sep 30 2020 | n/a | n/a | -US$36m |
| Jun 30 2020 | n/a | n/a | -US$32m |
| Mar 31 2020 | n/a | n/a | -US$31m |
| Dec 31 2019 | US$4m | US$525k | -US$26m |
| Sep 30 2019 | n/a | n/a | -US$24m |
| Jun 30 2019 | n/a | n/a | -US$24m |
| Mar 31 2019 | n/a | n/a | -US$23m |
| Dec 31 2018 | US$1m | US$485k | -US$22m |
| Sep 30 2018 | n/a | n/a | -US$21m |
| Jun 30 2018 | n/a | n/a | -US$20m |
| Mar 31 2018 | n/a | n/a | -US$19m |
| Dec 31 2017 | US$805k | US$440k | -US$21m |
Tazminat ve Piyasa: Brian's total compensation ($USD12.63M) is above average for companies of similar size in the US market ($USD8.06M).
Tazminat ve Kazançlar: Brian's compensation has increased whilst the company is unprofitable.
CEO
Brian Lian (58 yo)
12.2yrs
Görev süresi
US$12,628,061
Tazminat
Dr. Brian Lian, Ph D., served as Director at Apricus Biosciences, Inc. He has been the Chief Executive Officer and President at Viking Therapeutics, Inc. since September 24, 2012. Dr. Lian has been an Inde...
Liderlik Ekibi
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| President | 12.2yrs | US$12.63m | 1.71% $ 139.2m | |
| Chief Financial Officer | 5.3yrs | US$3.50m | 0.0010% $ 83.7k | |
| Chief Operating Officer | 3.8yrs | US$3.51m | 0.18% $ 15.0m | |
| Vice President of Finance & Administration | 6.6yrs | US$619.56k | Veri yok | |
| Senior Vice President of Pharmaceutical Development | 1.8yrs | Veri yok | Veri yok |
5.3yrs
Ortalama Görev Süresi
58.5yo
Ortalama Yaş
Deneyimli Yönetim: VKTX's management team is seasoned and experienced (5.3 years average tenure).
Yönetim Kurulu Üyeleri
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| President | 12.2yrs | US$12.63m | 1.71% $ 139.2m | |
| Scientific Advisor | no data | Veri yok | Veri yok | |
| Independent Director | 10.5yrs | US$169.37k | 0.10% $ 8.1m | |
| Independent Director | 10.5yrs | US$192.77k | 0.0085% $ 692.8k | |
| Independent Director | 7.3yrs | US$189.62k | 0.027% $ 2.2m | |
| Scientific Advisor | no data | Veri yok | Veri yok | |
| Scientific Advisor | no data | Veri yok | Veri yok | |
| Scientific Advisor | no data | Veri yok | Veri yok | |
| Scientific Advisor | no data | Veri yok | Veri yok | |
| Independent Chairman | 10.5yrs | US$222.72k | 0.043% $ 3.5m | |
| Scientific Advisor | no data | Veri yok | Veri yok | |
| Independent Director | 5.3yrs | US$178.65k | 0% $ 0 |
10.5yrs
Ortalama Görev Süresi
63.5yo
Ortalama Yaş
Deneyimli Yönetim Kurulu: VKTX's board of directors are seasoned and experienced ( 10.5 years average tenure).